$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

$arwr Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000162828024049277 Filed on November 26, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2024
Revenue		$0.00	$3.551M
YoY Change		-100.0%	-98.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$28.29M	$107.9M
YoY Change		5.63%	6.47%
% of Gross Profit
Research & Development		$128.9M	$505.9M
YoY Change		37.43%	43.23%
% of Gross Profit
Depreciation & Amortization		$5.025M	$16.90M
YoY Change		29.08%	57.94%
% of Gross Profit
Operating Expenses		$162.2M	$604.6M
YoY Change		30.36%	35.65%
Operating Profit			-$601.1M
YoY Change			193.21%
Interest Expense		-$7.477M	-$9.632M
YoY Change		442.99%	-152.56%
% of Operating Profit
Other Income/Expense, Net		-$3.118M	-$11.38M
YoY Change		-534.87%	664.27%
Pretax Income		-$172.8M	-$612.5M
YoY Change		58.54%	196.6%
Income Tax		$546.0K	-$2.767M
% Of Pretax Income
Net Earnings		-$170.5M	-$599.5M
YoY Change		55.49%	192.04%
Net Earnings / Revenue			-16882.37%
Basic Earnings Per Share			-$5.00
Diluted Earnings Per Share		-$1.37	-$5.00
COMMON SHARES
Basic Shares Outstanding	124.4M shares	124.3M shares	119.8M shares
Diluted Shares Outstanding			119.8M shares

Balance Sheet

Concept	2024 Q3	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$681.0M	$677.5M
YoY Change	68.73%	71.21%
Cash & Equivalents	$102.7M	$99.19M
Short-Term Investments	$578.3M	$578.3M
Other Short-Term Assets	$4.973M	$18.01M
YoY Change	-29.78%	-24.33%
Inventory
Prepaid Expenses	$9.537M
Receivables
Other Receivables
Total Short-Term Assets	$695.5M	$695.5M
YoY Change	65.78%	65.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$386.0M	$431.3M
YoY Change	32.99%	28.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.482M	$4.482M
YoY Change	2034.29%	2141.0%
Total Long-Term Assets	$444.3M	$444.3M
YoY Change	28.41%	28.38%
TOTAL ASSETS
Total Short-Term Assets	$695.5M	$695.5M
Total Long-Term Assets	$444.3M	$444.3M
Total Assets	$1.140B	$1.140B
YoY Change	48.89%	48.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.39M	$11.39M
YoY Change	-68.25%	-68.28%
Accrued Expenses	$63.02M	$91.35M
YoY Change	58.48%	33.75%
Deferred Revenue	$0.00
YoY Change	-100.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$103.2M	$103.2M
YoY Change	-2.17%	-2.21%
LONG-TERM LIABILITIES
Long-Term Debt	$393.2M	$393.2M
YoY Change
Other Long-Term Liabilities	$452.4M	$452.4M
YoY Change	21.31%	21.32%
Total Long-Term Liabilities	$845.6M	$845.6M
YoY Change	126.73%	126.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$103.2M	$103.2M
Total Long-Term Liabilities	$845.6M	$845.6M
Total Liabilities	$948.7M	$954.4M
YoY Change	98.32%	93.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.626B
YoY Change	58.43%
Common Stock	$1.806B
YoY Change	38.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$185.4M	$185.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.140B	$1.140B
YoY Change	48.89%	48.88%

Cashflow Statement

Concept	2024 Q3	2024
OPERATING ACTIVITIES
Net Income	-$170.5M	-$599.5M
YoY Change	55.49%	192.04%
Depreciation, Depletion And Amortization	$5.025M	$16.90M
YoY Change	29.08%	57.94%
Cash From Operating Activities	-$137.2M	-$462.9M
YoY Change	442.57%	200.77%
INVESTING ACTIVITIES
Capital Expenditures	$24.29M	$141.5M
YoY Change	-62.01%	-19.96%
Acquisitions
YoY Change
Other Investing Activities	-$198.6M	-$278.6M
YoY Change	-310.46%	-445.66%
Cash From Investing Activities	-$222.9M	-$420.1M
YoY Change	-829.82%	336.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$429.3M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	389.1M	$870.5M
YoY Change	254206.54%	244.01%
NET CHANGE
Cash From Operating Activities	-137.2M	-$462.9M
Cash From Investing Activities	-222.9M	-$420.1M
Cash From Financing Activities	389.1M	$870.5M
Net Change In Cash	28.95M	-$12.40M
YoY Change	435.32%	-512.33%
FREE CASH FLOW
Cash From Operating Activities	-$137.2M	-$462.9M
Capital Expenditures	$24.29M	$141.5M
Free Cash Flow	-$161.5M	-$604.3M
YoY Change	81.0%	82.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3054000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	191063000	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-609693000	usd
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0000879407
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-38042
CY2024	dei	Entity Registrant Name EntityRegistrantName	ARROWHEAD PHARMACEUTICALS, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-0408024
CY2024	dei	City Area Code CityAreaCode	626
CY2024	dei	Local Phone Number LocalPhoneNumber	304-3400
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	177 E. Colorado Blvd
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 700
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Pasadena
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91105
CY2024	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2024	dei	Trading Symbol TradingSymbol	ARWR
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	false
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024Q1	dei	Entity Public Float EntityPublicFloat	3000000000.0	usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	124434442	shares
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108005000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184434000	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-3744000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-2000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45297000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10563000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	104608000	usd
CY2023	us-gaap	Lease Cost LeaseCost	13259000	usd
CY2022	us-gaap	Lease Cost LeaseCost	9763000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1400000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	300000	usd
CY2023	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	48391000	usd
CY2022	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	0	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	5204000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y6M
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024Q3	arwr	Accrued Capital Expenditure Current AccruedCapitalExpenditureCurrent	4206000	usd
CY2023Q3	arwr	Accrued Capital Expenditure Current AccruedCapitalExpenditureCurrent	14044000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7391000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6998000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63017000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39763000	usd
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024	ecd	Insider Trd Policies Proc Adopted Flag InsiderTrdPoliciesProcAdoptedFlag	true
CY2024	dei	Auditor Firm AuditorFirmId	185
CY2024	dei	Auditor Name AuditorName	KPMG LLP
CY2024	dei	Auditor Location AuditorLocation	San Diego, CA
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102685000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110891000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	578276000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	292735000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9537000	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8813000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	4973000	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	4033000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	695471000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	416472000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	386032000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290262000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8562000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10262000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45255000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45297000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4482000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3259000	usd
CY2024Q3	us-gaap	Assets Assets	1139802000	usd
CY2023Q3	us-gaap	Assets Assets	765552000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	11388000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	35866000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63017000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39763000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21989000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17963000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6342000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10563000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	866000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	432000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	435000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	103168000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	105456000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	111027000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	104608000	usd
CY2024Q3	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	341361000	usd
CY2023Q3	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	268326000	usd
CY2024Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	393183000	usd
CY2023Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	0	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	845571000	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	372934000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124376000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124376000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107312000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107312000	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	217000	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	200000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1806000000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1300395000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4750000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3222000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1625523000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1026030000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	185444000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	271343000	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	5619000	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	15819000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	191063000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	287162000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1139802000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	765552000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3551000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	240735000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	243231000	usd
CY2024	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	505870000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	353188000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	297307000	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	98761000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	92549000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	124431000	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	604631000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	445737000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	421738000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-601080000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-205002000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-178507000	usd
CY2024	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	22720000	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	15299000	usd
CY2022	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	5033000	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	32352000	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	18326000	usd
CY2022	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	0	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1748000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1538000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	765000	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11380000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1489000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5798000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-612460000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-206491000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-172709000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2767000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2784000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3785000	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-609693000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-209275000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-176494000	usd
CY2024	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10200000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4000000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-431000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-599493000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-205275000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-176063000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.00
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.92
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.67
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.00
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.92
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.67
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119784000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106750000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105426000	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119784000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106750000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105426000	shares
CY2024	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3775000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2964000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2024	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4197000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-122000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-67000	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-601721000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-212361000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-176561000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	408822000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	120893000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5185000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-67000	usd
CY2022	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	60000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-176494000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	418339000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	418339000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	78130000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2964000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-122000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-209275000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	287162000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	287162000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	73968000	usd
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2389000	usd
CY2024	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	429265000	usd
CY2024	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3775000	usd
CY2024	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4197000	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-609693000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-209275000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-176494000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	73968000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	78130000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	120893000	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18595000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12493000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10421000	usd
CY2024	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	3244000	usd
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	2017000	usd
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-2910000	usd
CY2024	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	23035000	usd
CY2023	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	18326000	usd
CY2022	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	0	usd
CY2024	us-gaap	Paid In Kind Interest PaidInKindInterest	9317000	usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2024	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-80000	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-4432000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1410000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8845000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1664000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11603000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19291000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5536000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	32998000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6589000	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	32117000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-14965000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	17750000	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-866000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-129183000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-112501000	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	2240000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	46590000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	13428000	usd
CY2024	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1200000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	65000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-462851000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-153890000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-136131000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	141469000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	176737000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52777000	usd
CY2024	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	720947000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	246141000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	223391000	usd
CY2024	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	442344000	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	326723000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	270751000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-420072000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-96155000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5417000	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	429265000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2024	arwr	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	50000000	usd
CY2023	arwr	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	250000000	usd
CY2022	arwr	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	0	usd
CY2024	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	392000000	usd
CY2023	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	577465000	usd
CY2024Q3	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent	837000	usd
CY2024Q3	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent	26000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	578276000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	295699000	usd
CY2023Q3	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent	3000	usd
CY2023Q3	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent	2967000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	292735000	usd
CY2024	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	3134000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2389000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3053000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5186000	usd
CY2024	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0	usd
CY2023	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0	usd
CY2022	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	60000000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	870520000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	253053000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	65186000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-12403000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3008000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-76362000	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4197000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-122000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-67000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110891000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102685000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110891000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108005000	usd
CY2024	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4206000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14044000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17578000	usd
CY2024	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	5000000	usd
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102700000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3500000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	578300000	usd
CY2024	arwr	Increase Decrease In Cash And Investments IncreaseDecreaseInCashAndInvestments	277300000	usd
CY2024Q3	arwr	Development Regulatory And Sales Milestones Payments DevelopmentRegulatoryAndSalesMilestonesPayments	2700000000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates.
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3500000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	7900000	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentration of Credit Risk</span></div>Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September 30, 2024 and 2023, the Company’s investments were primarily invested in money market funds, commercial paper, and corporate debt securities through highly rated financial institutions. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company also maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution.
CY2024	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	295700000	usd
CY2023	us-gaap	Other Comprehensive Income Reclassification Adjustment For Held To Maturity Transferred To Available For Sale Securities Before Tax OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax	-3000000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3551000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	240735000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	243231000	usd
CY2024Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	866000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	444053000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	332213000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58021000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41951000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	386032000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290262000	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16900000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10700000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8700000	usd
CY2024Q3	arwr	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	28069000	usd
CY2023Q3	arwr	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	12826000	usd
CY2024Q3	arwr	Accrued Research And Development Co Development Expense Current AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent	23351000	usd
CY2023Q3	arwr	Accrued Research And Development Co Development Expense Current AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent	5895000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1700000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1700000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1700000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1700000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	795000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	967000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8562000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124376000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124376000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107312000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107312000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45255000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6342000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	111027000	usd
CY2024	us-gaap	Lease Cost LeaseCost	16689000	usd
CY2024	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15456000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15799000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	14974000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	13619000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	13905000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	114790000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	188543000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	71174000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	117369000	usd
CY2024	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	3099000	usd
CY2024	arwr	Right Of Use Asset Adjustment In Exchange For Operating Lease Liability RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability	-29000	usd
CY2023	arwr	Right Of Use Asset Adjustment In Exchange For Operating Lease Liability RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability	17071000	usd
CY2022	arwr	Right Of Use Asset Adjustment In Exchange For Operating Lease Liability RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability	0	usd
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	11038000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	4500000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y6M
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4600465	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1978516	shares
CY2024Q3	arwr	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding	6891828	shares
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	67097000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	78130000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	120893000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2263477	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	58957	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	36.80
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	226004	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.64
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1978516	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.39
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13782840	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1975824	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	23.33
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y6M
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	13782840	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	3.69
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0457
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.864
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	25.61
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-582333000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-194639000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-170570000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-30127000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7852000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1708000	usd
CY2024	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-612460000	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-202491000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-172278000	usd
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	148000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1074000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	375000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1710000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	304000	usd
CY2024	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-3290000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3481000	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-2767000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2784000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3785000	usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2767000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2784000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3785000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.086
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.030
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.068
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.025
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.046
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.017
CY2024	arwr	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent	-0.009
CY2023	arwr	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent	-0.046
CY2022	arwr	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent	0
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	-0.012
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.007
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.011
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.017
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.270
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.205
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.284
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.005
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.014
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.022
CY2024Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	102716000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	60495000	usd
CY2024Q3	arwr	Deferred Tax Assets In Process Research And Development Cost DeferredTaxAssetsInProcessResearchAndDevelopmentCost	156015000	usd
CY2023Q3	arwr	Deferred Tax Assets In Process Research And Development Cost DeferredTaxAssetsInProcessResearchAndDevelopmentCost	75208000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	85428000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	66407000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	81556000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	59441000	usd
CY2024Q3	arwr	Deferred Tax Assets Right Of Use Assets Or Lease Liabilities DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities	27999000	usd
CY2023Q3	arwr	Deferred Tax Assets Right Of Use Assets Or Lease Liabilities DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities	25382000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10989000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10296000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	4078000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3082000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1384000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1523000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2843000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2636000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	473008000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	304470000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	448867000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	284626000	usd
CY2024Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	13155000	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	9878000	usd
CY2024Q3	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	10792000	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	9966000	usd
CY2024Q3	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	194000	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	0	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	24141000	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19844000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	448900000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	284600000	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14536000	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3481000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	654000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	9495000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3481000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1489000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3415000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3049000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2024	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1992000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16613000	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14536000	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3481000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	-3300000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	3500000	usd
CY2024Q3	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0	usd
CY2024	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3400000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2200000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1700000	usd
CY2023Q3	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	268326000	usd
CY2022Q3	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	0	usd
CY2024	arwr	Upfront Payment Received Liability Related To Sale Of Future Royalties UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties	0	usd
CY2023	arwr	Upfront Payment Received Liability Related To Sale Of Future Royalties UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties	250000000	usd
CY2024	arwr	Milestone Payment Received Liability Related To Sale Of Future Royalties MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties	50000000	usd
CY2023	arwr	Milestone Payment Received Liability Related To Sale Of Future Royalties MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties	0	usd
CY2024	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	23035000	usd
CY2023	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	18326000	usd
CY2024Q3	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	341361000	usd
CY2023Q3	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	268326000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-599493000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-205275000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-176063000	usd
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119784000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106750000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105426000	shares
CY2024	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119784000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106750000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105426000	shares
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.00
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.92
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.67
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.00
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.92
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.67
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4737000	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4053000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3885000	shares

Files In Submission

Name	View Source	Status
0001628280-24-049277-index-headers.html	Edgar Link	pending
0001628280-24-049277-index.html	Edgar Link	pending
0001628280-24-049277.txt	Edgar Link	pending
0001628280-24-049277-xbrl.zip	Edgar Link	pending
arrowhead-avoroxformofpr.htm	Edgar Link	pending
arrowhead-avoroxformofpr001.jpg	Edgar Link	pending
arrowhead-avoroxformofpr002.jpg	Edgar Link	pending
arrowhead-avoroxformofpr003.jpg	Edgar Link	pending
arrowhead-avoroxformofpr004.jpg	Edgar Link	pending
arrowhead-avoroxformofpr005.jpg	Edgar Link	pending
arrowhead-avoroxformofpr006.jpg	Edgar Link	pending
arrowhead-avoroxformofpr007.jpg	Edgar Link	pending
arrowhead-avoroxformofpr008.jpg	Edgar Link	pending
arrowhead-avoroxformofpr009.jpg	Edgar Link	pending
arrowhead-avoroxformofpr010.jpg	Edgar Link	pending
arrowhead-avoroxformofpr011.jpg	Edgar Link	pending
arrowhead-avoroxformofpr012.jpg	Edgar Link	pending
arrowhead-avoroxformofpr013.jpg	Edgar Link	pending
arrowhead-avoroxformofpr014.jpg	Edgar Link	pending
arrowhead-avoroxformofpr015.jpg	Edgar Link	pending
arrowhead-avoroxformofpr016.jpg	Edgar Link	pending
arrowhead-avoroxformofpr017.jpg	Edgar Link	pending
arrowhead-avoroxformofpr018.jpg	Edgar Link	pending
arrowhead-avoroxformofpr019.jpg	Edgar Link	pending
arrowhead-avoroxregistra.htm	Edgar Link	pending
arrowhead-avoroxregistra001.jpg	Edgar Link	pending
arrowhead-avoroxregistra002.jpg	Edgar Link	pending
arrowhead-avoroxregistra003.jpg	Edgar Link	pending
arrowhead-avoroxregistra004.jpg	Edgar Link	pending
arrowhead-avoroxregistra005.jpg	Edgar Link	pending
arrowhead-avoroxregistra006.jpg	Edgar Link	pending
arrowhead-avoroxregistra007.jpg	Edgar Link	pending
arrowhead-avoroxregistra008.jpg	Edgar Link	pending
arrowhead-avoroxregistra009.jpg	Edgar Link	pending
arrowhead-avoroxregistra010.jpg	Edgar Link	pending
arrowhead-avoroxregistra011.jpg	Edgar Link	pending
arrowhead-avoroxregistra012.jpg	Edgar Link	pending
arrowhead-avoroxregistra013.jpg	Edgar Link	pending
arrowhead-avoroxregistra014.jpg	Edgar Link	pending
arrowhead-avoroxregistra015.jpg	Edgar Link	pending
arrowhead-avoroxregistra016.jpg	Edgar Link	pending
arrowhead-avoroxregistra017.jpg	Edgar Link	pending
arrowhead-avoroxregistra018.jpg	Edgar Link	pending
arrowhead-avoroxregistra019.jpg	Edgar Link	pending
arrowhead-avoroxregistra020.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti.htm	Edgar Link	pending
arrowhead-avoroxsecuriti001.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti002.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti003.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti004.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti005.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti006.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti007.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti008.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti009.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti010.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti011.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti012.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti013.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti014.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti015.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti016.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti017.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti018.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti019.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti020.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti021.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti022.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti023.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti024.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti025.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti026.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti027.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti028.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti029.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti030.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti031.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti032.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti033.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti034.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti035.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti036.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti037.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti038.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti039.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti040.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti041.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti042.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti043.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti044.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti045.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti046.jpg	Edgar Link	pending
arrowhead-avoroxsecuriti047.jpg	Edgar Link	pending
arrowhead-financingagree.htm	Edgar Link	pending
arrowhead-financingagree001.jpg	Edgar Link	pending
arrowhead-financingagree002.jpg	Edgar Link	pending
arrowhead-financingagree003.jpg	Edgar Link	pending
arrowhead-financingagree004.jpg	Edgar Link	pending
arrowhead-financingagree005.jpg	Edgar Link	pending
arrowhead-financingagree006.jpg	Edgar Link	pending
arrowhead-financingagree007.jpg	Edgar Link	pending
arrowhead-financingagree008.jpg	Edgar Link	pending
arrowhead-financingagree009.jpg	Edgar Link	pending
arrowhead-financingagree010.jpg	Edgar Link	pending
arrowhead-financingagree011.jpg	Edgar Link	pending
arrowhead-financingagree012.jpg	Edgar Link	pending
arrowhead-financingagree013.jpg	Edgar Link	pending
arrowhead-financingagree014.jpg	Edgar Link	pending
arrowhead-financingagree015.jpg	Edgar Link	pending
arrowhead-financingagree016.jpg	Edgar Link	pending
arrowhead-financingagree017.jpg	Edgar Link	pending
arrowhead-financingagree018.jpg	Edgar Link	pending
arrowhead-financingagree019.jpg	Edgar Link	pending
arrowhead-financingagree020.jpg	Edgar Link	pending
arrowhead-financingagree021.jpg	Edgar Link	pending
arrowhead-financingagree022.jpg	Edgar Link	pending
arrowhead-financingagree023.jpg	Edgar Link	pending
arrowhead-financingagree024.jpg	Edgar Link	pending
arrowhead-financingagree025.jpg	Edgar Link	pending
arrowhead-financingagree026.jpg	Edgar Link	pending
arrowhead-financingagree027.jpg	Edgar Link	pending
arrowhead-financingagree028.jpg	Edgar Link	pending
arrowhead-financingagree029.jpg	Edgar Link	pending
arrowhead-financingagree030.jpg	Edgar Link	pending
arrowhead-financingagree031.jpg	Edgar Link	pending
arrowhead-financingagree032.jpg	Edgar Link	pending
arrowhead-financingagree033.jpg	Edgar Link	pending
arrowhead-financingagree034.jpg	Edgar Link	pending
arrowhead-financingagree035.jpg	Edgar Link	pending
arrowhead-financingagree036.jpg	Edgar Link	pending
arrowhead-financingagree037.jpg	Edgar Link	pending
arrowhead-financingagree038.jpg	Edgar Link	pending
arrowhead-financingagree039.jpg	Edgar Link	pending
arrowhead-financingagree040.jpg	Edgar Link	pending
arrowhead-financingagree041.jpg	Edgar Link	pending
arrowhead-financingagree042.jpg	Edgar Link	pending
arrowhead-financingagree043.jpg	Edgar Link	pending
arrowhead-financingagree044.jpg	Edgar Link	pending
arrowhead-financingagree045.jpg	Edgar Link	pending
arrowhead-financingagree046.jpg	Edgar Link	pending
arrowhead-financingagree047.jpg	Edgar Link	pending
arrowhead-financingagree048.jpg	Edgar Link	pending
arrowhead-financingagree049.jpg	Edgar Link	pending
arrowhead-financingagree050.jpg	Edgar Link	pending
arrowhead-financingagree051.jpg	Edgar Link	pending
arrowhead-financingagree052.jpg	Edgar Link	pending
arrowhead-financingagree053.jpg	Edgar Link	pending
arrowhead-financingagree054.jpg	Edgar Link	pending
arrowhead-financingagree055.jpg	Edgar Link	pending
arrowhead-financingagree056.jpg	Edgar Link	pending
arrowhead-financingagree057.jpg	Edgar Link	pending
arrowhead-financingagree058.jpg	Edgar Link	pending
arrowhead-financingagree059.jpg	Edgar Link	pending
arrowhead-financingagree060.jpg	Edgar Link	pending
arrowhead-financingagree061.jpg	Edgar Link	pending
arrowhead-financingagree062.jpg	Edgar Link	pending
arrowhead-financingagree063.jpg	Edgar Link	pending
arrowhead-financingagree064.jpg	Edgar Link	pending
arrowhead-financingagree065.jpg	Edgar Link	pending
arrowhead-financingagree066.jpg	Edgar Link	pending
arrowhead-financingagree067.jpg	Edgar Link	pending
arrowhead-financingagree068.jpg	Edgar Link	pending
arrowhead-financingagree069.jpg	Edgar Link	pending
arrowhead-financingagree070.jpg	Edgar Link	pending
arrowhead-financingagree071.jpg	Edgar Link	pending
arrowhead-financingagree072.jpg	Edgar Link	pending
arrowhead-financingagree073.jpg	Edgar Link	pending
arrowhead-financingagree074.jpg	Edgar Link	pending
arrowhead-financingagree075.jpg	Edgar Link	pending
arrowhead-financingagree076.jpg	Edgar Link	pending
arrowhead-financingagree077.jpg	Edgar Link	pending
arrowhead-financingagree078.jpg	Edgar Link	pending
arrowhead-financingagree079.jpg	Edgar Link	pending
arrowhead-financingagree080.jpg	Edgar Link	pending
arrowhead-financingagree081.jpg	Edgar Link	pending
arrowhead-financingagree082.jpg	Edgar Link	pending
arrowhead-financingagree083.jpg	Edgar Link	pending
arrowhead-financingagree084.jpg	Edgar Link	pending
arrowhead-financingagree085.jpg	Edgar Link	pending
arrowhead-financingagree086.jpg	Edgar Link	pending
arrowhead-financingagree087.jpg	Edgar Link	pending
arrowhead-financingagree088.jpg	Edgar Link	pending
arrowhead-financingagree089.jpg	Edgar Link	pending
arrowhead-financingagree090.jpg	Edgar Link	pending
arrowhead-financingagree091.jpg	Edgar Link	pending
arrowhead-financingagree092.jpg	Edgar Link	pending
arrowhead-financingagree093.jpg	Edgar Link	pending
arrowhead-financingagree094.jpg	Edgar Link	pending
arrowhead-financingagree095.jpg	Edgar Link	pending
arrowhead-financingagree096.jpg	Edgar Link	pending
arrowhead-financingagree097.jpg	Edgar Link	pending
arrowhead-financingagree098.jpg	Edgar Link	pending
arrowhead-financingagree099.jpg	Edgar Link	pending
arrowhead-financingagree100.jpg	Edgar Link	pending
arrowhead-financingagree101.jpg	Edgar Link	pending
arrowhead-financingagree102.jpg	Edgar Link	pending
arrowhead-financingagree103.jpg	Edgar Link	pending
arrowhead-financingagree104.jpg	Edgar Link	pending
arrowhead-financingagree105.jpg	Edgar Link	pending
arrowhead-financingagree106.jpg	Edgar Link	pending
arrowhead-financingagree107.jpg	Edgar Link	pending
arrowhead-financingagree108.jpg	Edgar Link	pending
arrowhead-financingagree109.jpg	Edgar Link	pending
arrowhead-financingagree110.jpg	Edgar Link	pending
arrowhead-financingagree111.jpg	Edgar Link	pending
arrowhead-financingagree112.jpg	Edgar Link	pending
arrowhead-financingagree113.jpg	Edgar Link	pending
arrowhead-financingagree114.jpg	Edgar Link	pending
arrowhead-financingagree115.jpg	Edgar Link	pending
arrowhead-financingagree116.jpg	Edgar Link	pending
arrowhead-financingagree117.jpg	Edgar Link	pending
arrowhead-financingagree118.jpg	Edgar Link	pending
arrowhead-financingagree119.jpg	Edgar Link	pending
arrowhead-financingagree120.jpg	Edgar Link	pending
arrowhead-financingagree121.jpg	Edgar Link	pending
arrowhead-financingagree122.jpg	Edgar Link	pending
arrowhead-financingagree123.jpg	Edgar Link	pending
arrowhead-financingagree124.jpg	Edgar Link	pending
arrowhead-financingagree125.jpg	Edgar Link	pending
arrowhead-financingagree126.jpg	Edgar Link	pending
arrowhead-financingagree127.jpg	Edgar Link	pending
arrowhead-financingagree128.jpg	Edgar Link	pending
arrowhead-financingagree129.jpg	Edgar Link	pending
arrowhead-financingagree130.jpg	Edgar Link	pending
arrowhead-financingagree131.jpg	Edgar Link	pending
arrowhead-financingagree132.jpg	Edgar Link	pending
arrowhead-financingagree133.jpg	Edgar Link	pending
arrowhead-financingagree134.jpg	Edgar Link	pending
arrowhead-financingagree135.jpg	Edgar Link	pending
arrowhead-financingagree136.jpg	Edgar Link	pending
arrowhead-financingagree137.jpg	Edgar Link	pending
arrowhead-financingagree138.jpg	Edgar Link	pending
arrowhead-financingagree139.jpg	Edgar Link	pending
arrowhead-financingagree140.jpg	Edgar Link	pending
arrowhead-financingagree141.jpg	Edgar Link	pending
arrowhead-financingagree142.jpg	Edgar Link	pending
arrowhead-financingagree143.jpg	Edgar Link	pending
arrowhead-financingagree144.jpg	Edgar Link	pending
arrowhead-financingagree145.jpg	Edgar Link	pending
arrowhead-financingagree146.jpg	Edgar Link	pending
arrowhead-financingagree147.jpg	Edgar Link	pending
arrowhead-financingagree148.jpg	Edgar Link	pending
arrowhead-financingagree149.jpg	Edgar Link	pending
arrowhead-financingagree150.jpg	Edgar Link	pending
arrowhead-rsjconsent.htm	Edgar Link	pending
arrowhead-rsjconsent001.jpg	Edgar Link	pending
arrowhead-sareptaxinvest.htm	Edgar Link	pending
arrowhead-sareptaxinvest001.jpg	Edgar Link	pending
arrowhead-sareptaxinvest002.jpg	Edgar Link	pending
arrowhead-sareptaxinvest003.jpg	Edgar Link	pending
arrowhead-sareptaxinvest004.jpg	Edgar Link	pending
arrowhead-sareptaxinvest005.jpg	Edgar Link	pending
arrowhead-sareptaxinvest006.jpg	Edgar Link	pending
arrowhead-sareptaxinvest007.jpg	Edgar Link	pending
arrowhead-sareptaxinvest008.jpg	Edgar Link	pending
arrowhead-sareptaxinvest009.jpg	Edgar Link	pending
arrowhead-sareptaxinvest010.jpg	Edgar Link	pending
arrowhead-sareptaxinvest011.jpg	Edgar Link	pending
arrowhead-sareptaxinvest012.jpg	Edgar Link	pending
arrowhead-sareptaxinvest013.jpg	Edgar Link	pending
arrowhead-sareptaxinvest014.jpg	Edgar Link	pending
arrowhead-sareptaxinvest015.jpg	Edgar Link	pending
arrowhead-sareptaxinvest016.jpg	Edgar Link	pending
arrowhead-sareptaxinvest017.jpg	Edgar Link	pending
arrowhead-sareptaxinvest018.jpg	Edgar Link	pending
arrowhead-sareptaxinvest019.jpg	Edgar Link	pending
arrowhead-sareptaxinvest020.jpg	Edgar Link	pending
arrowhead-sareptaxinvest021.jpg	Edgar Link	pending
arrowhead-sareptaxstockp.htm	Edgar Link	pending
arrowhead-sareptaxstockp001.jpg	Edgar Link	pending
arrowhead-sareptaxstockp002.jpg	Edgar Link	pending
arrowhead-sareptaxstockp003.jpg	Edgar Link	pending
arrowhead-sareptaxstockp004.jpg	Edgar Link	pending
arrowhead-sareptaxstockp005.jpg	Edgar Link	pending
arrowhead-sareptaxstockp006.jpg	Edgar Link	pending
arrowhead-sareptaxstockp007.jpg	Edgar Link	pending
arrowhead-sareptaxstockp008.jpg	Edgar Link	pending
arrowhead-sareptaxstockp009.jpg	Edgar Link	pending
arrowhead-sareptaxstockp010.jpg	Edgar Link	pending
arrowhead-sareptaxstockp011.jpg	Edgar Link	pending
arrowhead-sareptaxstockp012.jpg	Edgar Link	pending
arrowhead-sareptaxstockp013.jpg	Edgar Link	pending
arrowhead-sareptaxstockp014.jpg	Edgar Link	pending
arrowhead-sareptaxstockp015.jpg	Edgar Link	pending
arrowhead-sareptaxstockp016.jpg	Edgar Link	pending
arrowhead-sareptaxstockp017.jpg	Edgar Link	pending
arrowhead-sareptaxstockp018.jpg	Edgar Link	pending
arrowhead-sareptaxstockp019.jpg	Edgar Link	pending
arrowhead-sareptaxstockp020.jpg	Edgar Link	pending
arrowhead-sareptaxstockp021.jpg	Edgar Link	pending
arrowhead-sareptaxstockp022.jpg	Edgar Link	pending
arrowhead-sareptaxstockp023.jpg	Edgar Link	pending
arrowhead-sareptaxstockp024.jpg	Edgar Link	pending
arrowhead-sareptaxstockp025.jpg	Edgar Link	pending
arrowhead-sareptaxstockp026.jpg	Edgar Link	pending
arrowhead-sareptaxstockp027.jpg	Edgar Link	pending
arrowhead-sareptaxstockp028.jpg	Edgar Link	pending
arrowhead-sareptaxstockp029.jpg	Edgar Link	pending
arrowhead-sareptaxstockp030.jpg	Edgar Link	pending
arrowhead-sareptaxstockp031.jpg	Edgar Link	pending
arrowhead-sareptaxstockp032.jpg	Edgar Link	pending
arrowhead-sareptaxstockp033.jpg	Edgar Link	pending
arrowhead-sareptaxstockp034.jpg	Edgar Link	pending
arrowhead-sareptaxstockp035.jpg	Edgar Link	pending
arrowhead-sareptaxstockp036.jpg	Edgar Link	pending
arrowhead-sareptaxstockp037.jpg	Edgar Link	pending
arrowhead-sareptaxstockp038.jpg	Edgar Link	pending
arrowhead-sareptaxstockp039.jpg	Edgar Link	pending
arrowhead-sareptaxstockp040.jpg	Edgar Link	pending
arrowhead-sareptaxstockp041.jpg	Edgar Link	pending
arrowhead-sareptaxstockp042.jpg	Edgar Link	pending
arrowhead-sareptaxstockp043.jpg	Edgar Link	pending
arrowhead-sareptaxstockp044.jpg	Edgar Link	pending
arrowhead-sareptaxstockp045.jpg	Edgar Link	pending
arrowhead-sareptaxstockp046.jpg	Edgar Link	pending
arrowhead-sareptaxstockp047.jpg	Edgar Link	pending
arrowhead-sareptaxstockp048.jpg	Edgar Link	pending
arrowhead-sareptaxstockp049.jpg	Edgar Link	pending
arrowhead-sareptaxstockp050.jpg	Edgar Link	pending
arrowhead-sareptaxstockp051.jpg	Edgar Link	pending
arrowhead-sareptaxstockp052.jpg	Edgar Link	pending
arrowhead-sareptaxstockp053.jpg	Edgar Link	pending
arrowhead-sareptaxstockp054.jpg	Edgar Link	pending
arrowhead-sareptaxstockp055.jpg	Edgar Link	pending
arrowhead-sareptaxstockp056.jpg	Edgar Link	pending
arrowhead-sareptaxstockp057.jpg	Edgar Link	pending
arrowhead-sareptaxstockp058.jpg	Edgar Link	pending
arrowhead-sareptaxstockp059.jpg	Edgar Link	pending
arrowhead-sareptaxstockp060.jpg	Edgar Link	pending
arrowhead-sareptaxstockp061.jpg	Edgar Link	pending
arrowhead-sareptaxstockp062.jpg	Edgar Link	pending
arrowhead-sareptaxstockp063.jpg	Edgar Link	pending
arrowhead-sareptaxstockp064.jpg	Edgar Link	pending
arrowhead-sareptaxstockp065.jpg	Edgar Link	pending
arrowhead-sareptaxstockp066.jpg	Edgar Link	pending
arrowhead-sareptaxstockp067.jpg	Edgar Link	pending
arrowhead-sareptaxstockp068.jpg	Edgar Link	pending
arrowhead-sareptaxstockp069.jpg	Edgar Link	pending
arwr-20240930.htm	Edgar Link	pending
arwr-20240930.xsd	Edgar Link	pending
arwr-20240930xex311.htm	Edgar Link	pending
arwr-20240930xex311001.jpg	Edgar Link	pending
arwr-20240930xex321.htm	Edgar Link	pending
arwr-20240930xex321001.jpg	Edgar Link	pending
arwr-20240930_g1.jpg	Edgar Link	pending
arwr-20240930_g2.jpg	Edgar Link	pending
arwr-20240930_g3.jpg	Edgar Link	pending
arwr-20240930_g4.jpg	Edgar Link	pending
arwr-20240930_g5.jpg	Edgar Link	pending
arwr-2024930xex312.htm	Edgar Link	pending
arwr-2024930xex312001.jpg	Edgar Link	pending
arwr-2024930xex322.htm	Edgar Link	pending
arwr-2024930xex322001.jpg	Edgar Link	pending
arwr-insidertradingpolic.htm	Edgar Link	pending
arwr-insidertradingpolic001.jpg	Edgar Link	pending
arwr-insidertradingpolic002.jpg	Edgar Link	pending
arwr-insidertradingpolic003.jpg	Edgar Link	pending
arwr-insidertradingpolic004.jpg	Edgar Link	pending
arwr-insidertradingpolic005.jpg	Edgar Link	pending
arwr-insidertradingpolic006.jpg	Edgar Link	pending
finalconsent-kpmg.htm	Edgar Link	pending
finalconsent-kpmg001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
arwr-20240930_cal.xml	Edgar Link	unprocessable
arwr-20240930_lab.xml	Edgar Link	unprocessable
arwr-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
arwr-20240930_def.xml	Edgar Link	unprocessable
arwr-20240930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

2024 Q4 Form 10-K Financial Statement

#000162828024049277 Filed on November 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARWR ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

2024 Q4 Form 10-K Financial Statement

#000162828024049277 Filed on November 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr